Pediatric Intensive Care Unit, Gregorio Marañón General University Hospital, Calle Doctor Castelo 47, 28009, Madrid, Spain.
Gregorio Marañón, Health Research Institute, Pabellón de Gobierno. Doctor Esquerdo 46, 28007, Madrid, Spain.
Trials. 2020 Apr 19;21(1):341. doi: 10.1186/s13063-020-4218-2.
Post-extubation upper airway obstruction (UAO) is a frequent complication causing stridor and respiratory distress, which occasionally require reintubation, thereby increasing morbidity and mortality rates. Contradictory results have been obtained in studies assessing the effectiveness of steroids in preventing post-extubation UAO, and the available evidence is limited. We designed a multicentric randomized, placebo-controlled study to explore the effectiveness of dexamethasone in preventing post-extubation UAO in children.
A multicentric, prospective, double-blind, randomized, placebo-controlled, phase IV clinical trial has been designed. The sample will include pediatric patients who are between 1 month and 16 years of age and who have been intubated for more than 48 h. Patients who have airway disorders or who have received steroids within the previous seven days will be excluded. Patients will be randomly assigned to receive either placebo or a therapy with dexamethasone 0.25 mg/kg every 6 h to be started 6 to 12 h prior to extubation (to a total of four doses). Randomization will be performed at a 1:1 ratio. Follow-up of patients will be carried out for 48 h after extubation. The main objective of this study is to access the reduction in the incidence of moderate to severe UAO symptoms following extubation. Secondary objectives include assessing the decrease in the incidence of reintubation, evaluating the use of additional therapies for UAO, and monitoring potential side effects of dexamethasone.
The results of this study will contribute to the existing evidence on prophylaxis for post-extubation airway obstruction.
EudraCT identifier: 2009-016596-30. Registered on May 11, 2010.
拔管后上气道梗阻(UAO)是一种常见的并发症,可导致喘鸣和呼吸困难,偶尔需要重新插管,从而增加发病率和死亡率。评估类固醇预防拔管后 UAO 有效性的研究结果相互矛盾,且现有证据有限。我们设计了一项多中心随机、安慰剂对照研究,以探讨地塞米松预防儿童拔管后 UAO 的有效性。
设计了一项多中心、前瞻性、双盲、随机、安慰剂对照、四期临床试验。该样本将包括年龄在 1 个月至 16 岁之间、插管时间超过 48 小时的儿科患者。将排除有气道疾病或在过去 7 天内接受过类固醇治疗的患者。患者将被随机分配接受安慰剂或地塞米松 0.25mg/kg,每 6 小时一次,在拔管前 6 至 12 小时开始(总共 4 剂)。随机分组比例为 1:1。拔管后 48 小时对患者进行随访。本研究的主要目的是评估拔管后中度至重度 UAO 症状发生率的降低。次要目标包括评估重新插管的发生率降低、评估 UAO 额外治疗的使用情况以及监测地塞米松的潜在副作用。
该研究的结果将有助于现有的拔管后气道梗阻预防证据。
EudraCT 标识符:2009-016596-30。于 2010 年 5 月 11 日注册。